PMID- 24669876
OWN - NLM
STAT- MEDLINE
DCOM- 20150608
LR  - 20221207
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 30
IP  - 7
DP  - 2014 Jul
TI  - Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes 
      mellitus: a double blind, randomized comparison with pioglitazone.
PG  - 1257-66
LID - 10.1185/03007995.2014.909393 [doi]
AB  - OBJECTIVE: To compare efficacy and safety of hydroxychloroquine with pioglitazone 
      in type 2 diabetes mellitus (T2DM). RESEARCH DESIGN AND METHODS: This 
      double-blind study randomized 267 uncontrolled type 2 diabetes patients (HbA1c 
      >/=7.5% and </=11.5%), post 3 months' treatment with glimepiride/gliclazide and 
      metformin, to additionally receive hydroxychloroquine 400 mg/day (n = 135) or 
      pioglitazone 15 mg/day (n = 132) for 24 weeks. Efficacy was assessed by changes 
      in HbA1c, fasting (FBG) and post-prandial (PPG) blood glucose at Week 12 and Week 
      24. RESULTS: At Week 12 and Week 24, HbA1c, FBG and PPG significantly reduced 
      from baseline in both groups. Mean reduction in glycemic parameters at Week 12 
      (HbA1c: -0.56% vs -0.72%, p = 0.394; FBG: -0.99 mmol/L vs -1.05 mmol/L, 
      p = 0.878; PPG: -1.93 mmol/L vs -1.52 mmol/L, p = 0.423) and Week 24 (HbA1c: 
      -0.87% vs -0.90%, p = 0.909; FBG: -0.79 mmol/L vs -1.02 mmol/L, p = 0.648; PPG: 
      -1.77 mmol/L vs -1.36 mmol/L, p = 0.415) was not significantly different between 
      the hydroxychloroquine and pioglitazone groups. Change in total cholesterol (TC) 
      and LDL-C was significant in favor of hydroxychloroquine (TC: -0.37 mmol/L vs 
      0.03 mmol/L, p = 0.002; LDL-C: -0.23 mmol/L vs 0.09 mmol/L, p = 0.003). 
      Triglycerides significantly reduced in both groups at Week 24. Mean HDL-C 
      remained unchanged. Study treatments were well tolerated. CONCLUSION: With 
      favorable effects on glycemic parameters and lipids, hydroxychloroquine may 
      emerge as well tolerated therapeutic option for T2DM. LIMITATIONS: The sample 
      size for this study was small. However, based on the encouraging results of this 
      proof-of-concept study, longer duration studies in larger population can be 
      conducted to further confirm these findings. TRIAL REGISTRATION DETAILS: Clinical 
      Trial Registry-India URL: http://ctri.nic.in, Registration Number: 
      CTRI/2009/091/001036.
FAU - Pareek, Anil
AU  - Pareek A
AD  - Medical Affairs and Clinical Research, Ipca Laboratories Limited , Mumbai , 
      India.
FAU - Chandurkar, Nitin
AU  - Chandurkar N
FAU - Thomas, Nihal
AU  - Thomas N
FAU - Viswanathan, Vijay
AU  - Viswanathan V
FAU - Deshpande, Alaka
AU  - Deshpande A
FAU - Gupta, O P
AU  - Gupta OP
FAU - Shah, Asha
AU  - Shah A
FAU - Kakrani, Arjun
AU  - Kakrani A
FAU - Bhandari, Sudhir
AU  - Bhandari S
FAU - Thulasidharan, N K
AU  - Thulasidharan NK
FAU - Saboo, Banshi
AU  - Saboo B
FAU - Devaramani, Shashidhar
AU  - Devaramani S
FAU - Vijaykumar, N B
AU  - Vijaykumar NB
FAU - Sharma, Shrikant
AU  - Sharma S
FAU - Agrawal, Navneet
AU  - Agrawal N
FAU - Mahesh, M
AU  - Mahesh M
FAU - Kothari, Kunal
AU  - Kothari K
LA  - eng
SI  - CTRI/CTRI/2009/091/001036
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20140502
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sulfonylurea Compounds)
RN  - 0 (Thiazolidinediones)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 4QWG6N8QKH (Hydroxychloroquine)
RN  - 6KY687524K (glimepiride)
RN  - 9100L32L2N (Metformin)
RN  - G4PX8C4HKV (Gliclazide)
RN  - X4OV71U42S (Pioglitazone)
SB  - IM
CIN - Curr Med Res Opin. 2015 Jun;31(6):1085-6. PMID: 25975357
CIN - Curr Med Res Opin. 2015 Jun;31(6):1087-92. PMID: 26020537
CIN - Curr Med Res Opin. 2015 Jun;31(6):1093-4. PMID: 26020538
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Biomarkers/blood
MH  - Blood Glucose/metabolism
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Gliclazide/therapeutic use
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Hydroxychloroquine/*therapeutic use
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Male
MH  - Metformin/therapeutic use
MH  - Middle Aged
MH  - Pioglitazone
MH  - Sulfonylurea Compounds/therapeutic use
MH  - Thiazolidinediones/*therapeutic use
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - Hydroxychloroquine
OT  - Metformin
OT  - Pioglitazone
OT  - Sulfonylurea
OT  - Type 2 diabetes mellitus
EDAT- 2014/03/29 06:00
MHDA- 2015/06/09 06:00
CRDT- 2014/03/28 06:00
PHST- 2014/03/28 06:00 [entrez]
PHST- 2014/03/29 06:00 [pubmed]
PHST- 2015/06/09 06:00 [medline]
AID - 10.1185/03007995.2014.909393 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2014 Jul;30(7):1257-66. doi: 10.1185/03007995.2014.909393. 
      Epub 2014 May 2.